On Jan. 20, the U.S. Food and Drug Administration (FDA) announced that testing positive for anti-JC virus antibodies has been identified as a risk factor for progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection associated with use of Tysabri (natalizumab) for the treatment of multiple sclerosis or Crohn’s disease. Read more.
© 2021 HealthCom Media All rights reserved. No part of this website or publication may be reproduced, stored, or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the copyright holder.